-
1
-
-
34248997600
-
-
Executive summary
-
Executive summary. Am J Kidney Dis 2004; 43: S16-S41.
-
(2004)
Am J Kidney Dis
, vol.43
-
-
-
2
-
-
0030034592
-
Blood pressure and end-stage renal disease in men
-
Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18.
-
(1996)
N Engl J Med
, vol.334
, pp. 13-18
-
-
Klag, M.J.1
Whelton, P.K.2
Randall, B.L.3
-
3
-
-
0036841387
-
Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies?
-
Locatelli F, Vecchio LD, D'amico M, Andrulli S: Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies? J Am Soc Nephrol 2002; 13: S196-S201.
-
(2002)
J Am Soc Nephrol
, vol.13
-
-
Locatelli, F.1
Vecchio, L.D.2
D'amico, M.3
Andrulli, S.4
-
4
-
-
0032513878
-
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
-
Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
-
(1998)
Lancet
, vol.351
, pp. 1755-1762
-
-
Hansson, L.1
Zanchetti, A.2
Carruthers, S.G.3
-
5
-
-
0028838569
-
Blood pressure control, proteinuria and the progression of renal diseases. The modification of diet in renal disease study
-
Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria and the progression of renal diseases. The modification of diet in renal disease study. Ann Intern Med 1995; 123: 754-762.
-
(1995)
Ann Intern Med
, vol.123
, pp. 754-762
-
-
Peterson, J.C.1
Adler, S.2
Burkart, J.M.3
-
6
-
-
0026481126
-
Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects
-
for the MRFIT Research Group
-
Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD, for the MRFIT Research Group: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. JAMA 1992; 268: 3085-3091.
-
(1992)
JAMA
, vol.268
, pp. 3085-3091
-
-
Walker, W.G.1
Neaton, J.D.2
Cutler, J.A.3
Neuwirth, R.4
Cohen, J.D.5
-
7
-
-
0032511580
-
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
-
UK Prospective Diabetes Study Group
-
UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
-
(1998)
BMJ
, vol.317
, pp. 703-713
-
-
-
8
-
-
0033069767
-
World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension
-
Guidelines Subcommittee
-
Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183.
-
(1999)
J Hypertens
, vol.1999
, Issue.17
, pp. 151-183
-
-
-
9
-
-
0030713021
-
Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
-
Joint National Committee on Prevention
-
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
-
(1997)
Arch Intern Med
, vol.157
, pp. 2413-2446
-
-
-
10
-
-
0347423198
-
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
-
Chobanian AV, Bakris GL, Black HR, et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
-
(2003)
Hypertension
, vol.42
, pp. 1206-1252
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
-
11
-
-
0344718782
-
World Health Organization (WHO) International Society of Hypertension (ISH) statement on management of hypertension
-
World Health Organization, International Society of Hypertension Writing Group
-
World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO) International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.
-
(2003)
J Hypertens
, vol.2003
, Issue.21
, pp. 1983-1992
-
-
-
12
-
-
0041810638
-
The role of arterial hypertension in the progression of non-diabetic glomerular diseases
-
Ljutić D, Kes P: The role of arterial hypertension in the progression of non-diabetic glomerular diseases. Nephrol Dial Transplant 2003; 18: S28-S30.
-
(2003)
Nephrol Dial Transplant
, vol.18
-
-
Ljutić, D.1
Kes, P.2
-
13
-
-
3242891578
-
Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases
-
Kojima S, Shida M, Yokoyama H: Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27: 379-385.
-
(2004)
Hypertens Res
, vol.27
, pp. 379-385
-
-
Kojima, S.1
Shida, M.2
Yokoyama, H.3
-
14
-
-
0035816018
-
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial
-
Agodoa L, Appel L, Bakris G, et al: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 2001; 285: 2719-2728.
-
(2001)
JAMA
, vol.285
, pp. 2719-2728
-
-
Agodoa, L.1
Appel, L.2
Bakris, G.3
-
15
-
-
0037031270
-
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect
-
for the Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators
-
Viberti G, Wheeldon NM, for the Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106: 672-678.
-
(2002)
Circulation
, vol.106
, pp. 672-678
-
-
Viberti, G.1
Wheeldon, N.M.2
-
16
-
-
0030668490
-
Efficacy and tolerability of valsartan compared with lisinopril in patients with hypertension and renal insufficiency
-
Perico N, Spormann D, Peruzzi E, Bodin F, Sioufi A, Bertocchi F: Efficacy and tolerability of valsartan compared with lisinopril in patients with hypertension and renal insufficiency. Clin Drug Invest 1997; 14: 252-259.
-
(1997)
Clin Drug Invest
, vol.14
, pp. 252-259
-
-
Perico, N.1
Spormann, D.2
Peruzzi, E.3
Bodin, F.4
Sioufi, A.5
Bertocchi, F.6
-
17
-
-
0035922441
-
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
-
Brenner BM, Cooper ME, Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
-
(2001)
N Engl J Med
, vol.345
, pp. 861-869
-
-
Brenner, B.M.1
Cooper, M.E.2
Zeeuw, D.3
-
18
-
-
0037145856
-
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK Trial
-
Wright JT, Bakris G, Greene T, et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK Trial. JAMA 2002; 288: 2421-2431.
-
(2002)
JAMA
, vol.288
, pp. 2421-2431
-
-
Wright, J.T.1
Bakris, G.2
Greene, T.3
-
19
-
-
0345516005
-
Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension
-
Plum J, Bünten B, Németh R, Grabensee B: Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998; 9: 2223-2234.
-
(1998)
J Am Soc Nephrol
, vol.9
, pp. 2223-2234
-
-
Plum, J.1
Bünten, B.2
Németh, R.3
Grabensee, B.4
-
20
-
-
0037378751
-
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy
-
Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14: 992-999.
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 992-999
-
-
Jacobsen, P.1
Andersen, S.2
Jensen, B.R.3
Parving, H.H.4
-
21
-
-
0037363248
-
Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses
-
Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM: Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. JRAAS 2003; 4: 43-47.
-
(2003)
JRAAS
, vol.4
, pp. 43-47
-
-
Segura, J.1
Praga, M.2
Campo, C.3
Rodicio, J.L.4
Ruilope, L.M.5
-
22
-
-
0642373661
-
How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: According to blood pressure or proteinuria?
-
Segura J, Christiansen H, Campo C, Ruilope LM: How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria? Curr Hypertens Rep 2003; 5: 426-429.
-
(2003)
Curr Hypertens Rep
, vol.5
, pp. 426-429
-
-
Segura, J.1
Christiansen, H.2
Campo, C.3
Ruilope, L.M.4
-
23
-
-
11244253140
-
Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency
-
Giri S, Mahajan SK, Sen R, Sharma A: Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency. J Assoc Physicians India 2002; 50: 1245-1250.
-
(2002)
J Assoc Physicians India
, vol.50
, pp. 1245-1250
-
-
Giri, S.1
Mahajan, S.K.2
Sen, R.3
Sharma, A.4
-
24
-
-
10744223299
-
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies
-
Campbell R, Sangalli F, Perticucci E, et al: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003: 63 1094-1103.
-
(2003)
Kidney Int
, vol.63
, pp. 1094-1103
-
-
Campbell, R.1
Sangalli, F.2
Perticucci, E.3
-
25
-
-
0345530947
-
Differing anti-proteinuric action of candesartan and losartan in chronic renal disease
-
Matsuda H, Hayashi K, Homma K, et al: Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertens Res 2003; 26: 875-880. 1
-
(2003)
Hypertens Res
, vol.26
, Issue.875-880
, pp. 1
-
-
Matsuda, H.1
Hayashi, K.2
Homma, K.3
-
26
-
-
1642502319
-
National Kidney Foundation practice guideline for chronic kidney disease, evaluation, classification, and stratification
-
Levey AS, Coresh J, Balk E, et al: National Kidney Foundation practice guideline for chronic kidney disease, evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-149.
-
(2003)
Ann Intern Med
, vol.139
, pp. 137-149
-
-
Levey, A.S.1
Coresh, J.2
Balk, E.3
-
27
-
-
0344305712
-
Hypertension control
-
Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowlitz DR: Hypertension control. Arch Intern Med 2003; 163: 2705-2711.
-
(2003)
Arch Intern Med
, vol.163
, pp. 2705-2711
-
-
Borzecki, A.M.1
Wong, A.T.2
Hickey, E.C.3
Ash, A.S.4
Berlowlitz, D.R.5
|